Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

NA masthead new 1

January 1, 2021

View Archives Issues

  • Neurotropism of COVID-19: What Is New?

    SARS-CoV-2 may gain access to the brain via the olfactory epithelium. The olfactory epithelium and bulbs may serve as an entry point for SARS-CoV-2 infection into the central nervous system.

  • Cranial Neuropathy in CIDP

    Cranial nerves are infrequently involved in typical chronic inflammatory demyelinating polyneuropathy, but involvement is more common in multifocal acquired demyelinating sensory and motor neuropathy (about 50%). The facial nerve is the most commonly affected cranial nerve, often bilateral.

  • Rapid Eye Movement Sleep Duration Is Predictive of Life Expectancy

    Total sleep duration declines with increasing age, as does the fraction of sleep spent in rapid eye movement (REM) sleep. The decline in REM is associated with increasing mortality, but it is not clear if this is a cause or a marker of declining health and declining brain function.

  • Rhabdomyolysis Etiology

    Rhabdomyolysis can be a life-threatening condition that often triggers a neurology consultation during an investigation for cause. However, in this recent study, the majority of cases (79%) were triggered by external, non-neuromuscular causes, and the others, although suspicious for an intrinsic muscular or genetic cause, rarely had a specific diagnosis confirmed.

  • Medical Therapy vs. Carotid Endarterectomy in Patients with Asymptomatic Carotid Stenosis

    Since the pivotal trials demonstrating the benefit of endarterectomy vs. medical therapy many years ago, there has been significant improvement in the risk factors for atherosclerosis, including better treatment of blood pressure and diabetes, as well as improved antiplatelet medication regimens and high-potency statins.

  • Ticagrelor, a New Antiplatelet Agent, Shows Promise in Secondary Prevention of Ischemic Stroke

    Ticagrelor is an antiplatelet agent that works by reversibly binding to P2Y12 adenosine diphosphate receptors on platelets, similar to the mechanism of action of clopidogrel. However, it is a direct-acting drug, and not a pro-drug, and does not need to be enzymatically converted to be active, like clopidogrel.

  • A Mobile Interventional Stroke Team (MIST) Shows Promise in Performing Rapid Thrombectomy

    Since 2015, when multiple international trials were reported showing clear benefit for mechanical thrombectomy in patients with large vessel occlusions, this treatment has been the standard of care. However, the speed of treatment remains paramount for good outcomes, and different models have been developed around the world in different geographic settings.